# REGLAT at ArGuard Shared Tasks: An Ensemble-Based Model Integrating NER for Harmful Content Detection in Arabic

Preprint · Ahmed M. Fetouh, Mariam Labib, Nsrin Ashraf, Omer Dawood, Hamada Nayel

- Archive id: arxiv:2610.37265
- Published: 2026-10-27
- arXiv: https://arxiv.org/abs/2610.37265
- Citations: 0
- Source URL: https://arxiv.org/abs/2610.37265
- PDF: https://arxiv.org/pdf/2610.37265
- Provenance: arxiv

## Abstract

Detecting harmful content in Arabic is challenging because of dialectal variations and the semantic overlap between different harm categories. This paper presents a two-stage approach for classifying Arabic user prompts into seven categories of harmful content. First, GLiNER is used to extract harm-related entities from each prompt. The extracted entities are then added to the original text and passed to a fine-tuned MARBERT classifier for final classification. The approach combines explicit entity information with the contextual understanding of a pretrained Arabic language model. The system was evaluated on the development set of the ArGuard 2026 shared task. The results achieved a macro-F1 score of 0.886 and an accuracy of 0.897, demonstrating promising performance in fine-grained harmful content detection. The system reported an accuracy of 0.793 and Macro-F score of 0.735 on a blind test set for subtask 1. For subtask 2, it achieved an accuracy of 0.770 and Macro-F score of 0.754. The analysis also showed that distinguishing between related categories remains challenging. These findings suggest that integrating NER with Arabic language models is a promising approach to harmful content detection.

_Abstract reproduced under CC0-1.0 (arXiv descriptive metadata)._

Topics: [LLM Architectures & Pretraining](https://space-kitty.com/topics/llm-architectures)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.